

**REMARKS**

Entry of the foregoing amendments are respectfully requested.

Should the Examiner have any questions concerning the subject application, a telephone call to the undersigned would be appreciated.

Respectfully submitted

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: 

Teresa Stanek Rea

Registration No. 30,427

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

**Date: March 29, 2002**

Attachment to Preliminary Amendment dated March 29, 2002

**Marked-up Claims 1 - 9 and 11**

1. (Amended) [Pharmaceutical mixture] A pharmaceutical composition comprising an effective amount of loteprednol or a pharmaceutically tolerable ester thereof and at least one antihistamine.
2. (Amended) [Mixture] The composition according to claim 1, [characterized in that] wherein the antihistamine is a topically administrable antihistamine.
3. (Amended) [Mixture] The composition according to [claims] claim 1 [or 2], [characterized in that] wherein the antihistamine is azelastine and/or levocabastine.
4. (Amended) [Mixture] The composition according to [one of the above claims] claim 1, [characterized in that] wherein the pharmaceutically tolerable ester is loteprednol etabonate.
5. (Amended) [Medicament] A method for the treatment of disorders of the lower and/or upper airways and/or for the treatment of allergies, comprising [as active compounds] administering to a patient in need thereof, an effective amount of loteprednol and at least one topically administrable antihistamine, [if appropriate] optionally together with customary excipients or vehicles, for simultaneous, sequential or separate administration.

**Attachment to Preliminary Amendment dated March 29, 2002**

**Marked-up Claims 1 - 9 and 11**

6. (Amended) [Medicament] The method according to claim 5, [characterized in that it can be administered] wherein such administration is intranasally or intraocularly simultaneously, in succession or independently of one another.

7. (Amended) [Medicament] The method according to [claims] claim 5 [or 6], [characterized in that it is] which is administered as an inhalable liquid or solid preparation.

8. (Amended) [Medicament] The method according to claim 5, [characterized in that the antihistamine can also be] which is administered orally.

9. (Amended) [Process for the preparation of a medicament] A method for the treatment and prophylaxis of airway disorders and/or allergies, comprising [as active compounds] administering to a patient in need thereof, an effective amount of loteprednol or a pharmaceutically tolerable ester thereof and at least one antihistamine, [characterized in that] wherein the loteprednol or a pharmaceutically tolerable ester thereof and the antihistamine(s) are mixed individually or together, optionally together with customary excipients or vehicles, and the mixture [thus obtained is converted into] is in a suitable administration [forms] form.

**Attachment to Preliminary Amendment dated March 29, 2002**

**Marked-up Claims 1 - 9 and 11**

11. (Amended) [Use of a combination of loteprednol or a pharmaceutically tolerable ester thereof and an antihistamine for simultaneous, sequential or separate administration for the production of a medicament] A method for the treatment of allergic rhinitis and rhinoconjunctivitis comprising administering to a patient in need thereof, a combination of loteprednol or a pharmaceutically tolerable ester thereof and an antihistamine for simultaneous, sequential or separate administration.